BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 28512126)

  • 1. Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma
    Lo PK; Zhang Y; Yao Y; Wolfson B; Yu J; Han SY; Duru N; Zhou Q
    J Biol Chem; 2017 Jul; 292(27):11466-11484. PubMed ID: 28512126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence.
    Allen MD; Thomas GJ; Clark S; Dawoud MM; Vallath S; Payne SJ; Gomm JJ; Dreger SA; Dickinson S; Edwards DR; Pennington CJ; Sestak I; Cuzick J; Marshall JF; Hart IR; Jones JL
    Clin Cancer Res; 2014 Jan; 20(2):344-57. PubMed ID: 24150233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.
    Duivenvoorden HM; Rautela J; Edgington-Mitchell LE; Spurling A; Greening DW; Nowell CJ; Molloy TJ; Robbins E; Brockwell NK; Lee CS; Chen M; Holliday A; Selinger CI; Hu M; Britt KL; Stroud DA; Bogyo M; Möller A; Polyak K; Sloane BF; O'Toole SA; Parker BS
    J Pathol; 2017 Dec; 243(4):496-509. PubMed ID: 29086922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis.
    Zubeldia-Plazaola A; Recalde-Percaz L; Moragas N; Alcaraz M; Chen X; Mancino M; Fernández-Nogueira P; Prats de Puig M; Guzman F; Noguera-Castells A; López-Plana A; Enreig E; Carbó N; Almendro V; Gascón P; Bragado P; Fuster G
    Breast Cancer Res; 2018 Jul; 20(1):65. PubMed ID: 29973218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function.
    Sarper M; Allen MD; Gomm J; Haywood L; Decock J; Thirkettle S; Ustaoglu A; Sarker SJ; Marshall J; Edwards DR; Jones JL
    Breast Cancer Res; 2017 Mar; 19(1):33. PubMed ID: 28330493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.
    Lee J; Kim HE; Song YS; Cho EY; Lee A
    Breast Cancer Res Treat; 2019 Jul; 176(1):119-130. PubMed ID: 30989460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells.
    Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T
    Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
    Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
    Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.
    Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S
    Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myoepithelial cell differentiation markers in ductal carcinoma in situ progression.
    Russell TD; Jindal S; Agunbiade S; Gao D; Troxell M; Borges VF; Schedin P
    Am J Pathol; 2015 Nov; 185(11):3076-89. PubMed ID: 26343330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of in situ to invasive breast carcinoma transition.
    Hu M; Yao J; Carroll DK; Weremowicz S; Chen H; Carrasco D; Richardson A; Violette S; Nikolskaya T; Nikolsky Y; Bauerlein EL; Hahn WC; Gelman RS; Allred C; Bissell MJ; Schnitt S; Polyak K
    Cancer Cell; 2008 May; 13(5):394-406. PubMed ID: 18455123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression.
    Logullo AF; Nonogaki S; Pasini FS; Osório CA; Soares FA; Brentani MM
    Oncol Rep; 2010 Feb; 23(2):313-20. PubMed ID: 20043090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of deregulated microRNAs in breast cancer progression using FFPE tissue.
    Chen L; Li Y; Fu Y; Peng J; Mo MH; Stamatakos M; Teal CB; Brem RF; Stojadinovic A; Grinkemeyer M; McCaffrey TA; Man YG; Fu SW
    PLoS One; 2013; 8(1):e54213. PubMed ID: 23372687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a stem-like subpopulation in basal-like ductal carcinoma in situ (DCIS) lesions.
    Li Q; Eades G; Yao Y; Zhang Y; Zhou Q
    J Biol Chem; 2014 Jan; 289(3):1303-12. PubMed ID: 24297178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus Inhibits the Progression of Ductal Carcinoma
    Chen G; Ding XF; Pressley K; Bouamar H; Wang B; Zheng G; Broome LE; Nazarullah A; Brenner AJ; Kaklamani V; Jatoi I; Sun LZ
    Clin Cancer Res; 2020 Mar; 26(6):1486-1496. PubMed ID: 31871301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy.
    Hong Y; Limback D; Elsarraj HS; Harper H; Haines H; Hansford H; Ricci M; Kaufman C; Wedlock E; Xu M; Zhang J; May L; Cusick T; Inciardi M; Redick M; Gatewood J; Winblad O; Aripoli A; Huppe A; Balanoff C; Wagner JL; Amin AL; Larson KE; Ricci L; Tawfik O; Razek H; Meierotto RO; Madan R; Godwin AK; Thompson J; Hilsenbeck SG; Futreal A; Thompson A; Hwang ES; Fan F; Behbod F;
    J Pathol; 2022 Feb; 256(2):186-201. PubMed ID: 34714554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation.
    Shah S; Brock EJ; Jackson RM; Ji K; Boerner JL; Sloane BF; Mattingly RR
    Neoplasia; 2018 Sep; 20(9):951-963. PubMed ID: 30144784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
    Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
    Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TBX3 promotes progression of pre-invasive breast cancer cells by inducing EMT and directly up-regulating SLUG.
    Krstic M; Kolendowski B; Cecchini MJ; Postenka CO; Hassan HM; Andrews J; MacMillan CD; Williams KC; Leong HS; Brackstone M; Torchia J; Chambers AF; Tuck AB
    J Pathol; 2019 Jun; 248(2):191-203. PubMed ID: 30697731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.